文献速递泌尿男性生殖肿瘤

质子与光子放疗治疗前列腺癌毒性比较的更新分析

Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2024-03-20

基于SEER-Medicare数据库纳入2010至2017年局限性前列腺癌患者,将772例质子束治疗(PBT)患者与1544例调强放疗(IMRT)患者按2:1匹配,比较治疗后6、12、24个月的胃肠(GI)和泌尿生殖(GU)毒性。观察性研究显示PBT与IMRT在GI或GU毒性方面无统计学显著差异。

要点

  • IMRT组与PBT组24个月GI毒性频率分别为20.5%与23.4%(P = .11),无统计学显著差异。
  • IMRT组与PBT组24个月GU毒性频率分别为28.2%与25.8%(P = .21),无统计学显著差异。
  • 仅基于操作代码的敏感性分析中,GI与GU毒性频率同样无显著差异。

核心结论

  • 在这项观察性研究中,PBT与IMRT在GI或GU毒性方面无统计学显著差异。

研究设计与样本

  • 研究利用SEER-Medicare关联数据库,识别2010至2017年诊断的局限性前列腺癌患者。
  • 按临床和社会人口学特征将接受IMRT与PBT的患者以2:1匹配。
  • 最终样本包括772例PBT患者匹配1544例IMRT患者,比较治疗后6、12、24个月的GI和GU毒性。
  • 敏感性分析仅基于操作代码识别毒性。

主要发现

  • IMRT组与PBT组GI毒性频率在6个月为3.5% vs 2.5%(P = .18),12个月为9.5% vs 10.2%(P = .18),24个月为20.5% vs 23.4%(P = .11)。
  • 仅基于操作代码的GI毒性频率在IMRT组与PBT组均太低而无法报告,且无显著差异。
  • IMRT组与PBT组GU毒性频率在6、12、24个月分别为6.8% vs 5.7%(P = .30)、14.3% vs 12.2%(P = .13)、28.2% vs 25.8%(P = .21)。
  • 仅基于操作代码时,IMRT组6个月GU毒性频率为1.0%,PBT组因太罕见而无法报告(P = .64);12个月IMRT组 vs PBT组为3.3% vs 2.1%(P = .10),24个月为8.7% vs 6.7%(P = .10)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Previous comparative effectiveness studies have not demonstrated a benefit of proton beam therapy (PBT) compared with intensity-modulated radiation therapy (IMRT) for prostate cancer. An updated comparison of GI and genitourinary (GU) toxicity is needed. METHODS: We investigated the SEER-Medicare linked database, identifying patients with localized prostate cancer diagnosed from 2010 to 2017. Procedure and diagnosis codes indicative of treatment-related toxicity were identified. As a sensitivity analysis, we also identified toxicity based only on procedure codes. Patients who underwent IMRT and PBT were matched 2:1 on the basis of clinical and sociodemographic characteristics. We then compared GI and GU toxicity at 6, 12, and 24 months after treatment. RESULTS: The final sample included 772 PBT patients matched to 1,544 IMRT patients. The frequency of GI toxicity for IMRT versus PBT was 3.5% versus 2.5% at 6 months (P = .18), 9.5% versus 10.2% at 12 months (P = .18), and 20.5% versus 23.4% at 24 months (P = .11). The frequency of only procedure codes indicative of GI toxicity for IMRT versus PBT was too low to be reported and not significantly different. The frequency of GU toxicity for IMRT versus PBT was 6.8% versus 5.7% (P = .30), 14.3% versus 12.2% (P = .13), and 28.2% versus 25.8% (P = .21) at 6, 12, and 24 months, respectively. When looking only at procedure codes, the frequency of GU toxicity for IMRT was 1.0% at 6 months, whereas it was too infrequent to report for PBT (P = .64). GU toxicity for IMRT versus PBT was 3.3% versus 2.1% (P = .10), and 8.7% versus 6.7% (P = .10) at 12 and 24 months, respectively. CONCLUSION: In this observational study, there were no statistically significant differences between PBT and IMRT in terms of GI or GU toxicity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Yu JB, DeStephano DM, Jeffers B, et al. Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer. J Clin Oncol. 2024. PMID: 38507655. doi:10.1200/JCO.23.01604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。